Feasibility and Safety of Collecting Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy
Phase 1
20
about 2.8 years
18–85
1 site in CA
What this study is about
Researchers are testing the safety and feasibility of collecting autologous hematopoietic stem cells to be combined with CAR T-cell therapy for people with relapsed/refractory hematological diseases. The trial will evaluate how well the target dose of HSCs can be collected from at least 50% of enrolled patients, as well as assess the safety of this combination treatment based on cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome in the first 60 days post CAR T dosing, along with adverse events and serious adverse events. It will follow an open-label, single-center design.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive autologous hematopoietic stem cells added to planned CAR T
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
cell therapy
Secondary: Assess safety and tolerability of combining aHSCs with an FDA-approved CAR T regimen within first 52 weeks of aHSC infusion., Median overall survival (OS) for the duration of the study, Median progression-free survival (PFS) for the duration of the study, Response rate of CAR T at 6 weeks.
Oncology